Inflammatory diseases are typified by an over-reaction
of the human immune system against either some trigger or, in some-cases,
without a specific trigger. Many diseases are caused by inflammation, however
delivery of anti-inflammatory drugs is not always easily accomplished due to
location or other disease complications. Recently, researchers at Stony Brook
University and Medicon Pharmaceuticals utilized PEG-PLA (Polyvivo AK005) from
PolyScitech (www.polyscitech.com)
to generate anti-inflammatory nanoparticles for delivery of Phospho-sulindac to
the ocular region. Read more: Robert A. Honkanen, Liqun Huang, Gang Xie, Basil
Rigas “Phospho-sulindac is efficacious in an improved concanavalin a-based
rabbit model of chronic dry eye disease” Translational Research (2018) https://www.sciencedirect.com/science/article/pii/S1931524418300562
“Abstract: Dry eye disease (DED), an inflammatory
disease of the ocular surface, affects 15% of humans worldwide. No satisfactory
treatment exists for DED partly due to the lack of informative animal models of
this disease. We evaluated the anti-inflammatory phosphosulindac (PS) for the
treatment of DED, using a new rabbit model of chronic DED. In this model, based
on the Concanavalin A (Con A) acute DED model, we injected weekly x3 all
lacrimal glands with ConA under ultrasound guidance, which prolonged DED to
>3 weeks; and used concurrently four parameters of efficacy: tear break up
time (TBUT), tear osmolarity, Schirmer's test, and tear lactoferrin levels,
making efficacy assessment robust. Rabbits with DED (n=8-10 eyes/group) were
treated topically with PS or vehicle 3x/day for 21 days. PS restored to normal
TBUT, tear osmolarity and lactoferrin levels (p<0 .0001="" 1="" 6="" 8="" a="" abbreviations:="" account="" acid="" activated="" activation="" activity="" albumin="" amp="" an="" and="" animal="" anti-inflammatory="" apparent="" assay="" b="" beta="" bovine="" break="" bsa="" buffered="" but="" c-jun="" cause="" cells="" completely="" con="" concanavalin="" concentration="" cornea.="" cornea="" corneal="" cyclosporine="" ded.="" ded="" deviation="" diclofenac="" did="" disease="" dodecyl="" drug="" drugs="" dry="" e2="" effect="" effects="" efficacious="" efficacy="" electophoretic="" elisa="" emsa="" enzyme-linked="" eosin="" erk="" error="" establish="" evaluation="" extracellular="" eye="" factor="" for="" further="" gland="" glycol-block-polylactic="" growth="" h="" had="" half="" hematoxylin="" ic50="" il-1="" il-6="" il-8="" ilg="" immunoprecipitation="" immunosorbent="" improve="" in="" indicate="" inferior="" inhibitory="" interleukin="" international="" its="" iu="" jnk="" kappa-light-chain-enhancer="" ketorolac="" kinases="" lacrimal="" levels="" lifitegrast.="" likely="" list="" mapks="" matrix="" maximal="" mean="" melt="" merits="" metalloproteinase="" milliliter="" minute="" mitogen="" ml="" mmp-1="" mmp-9="" mmp="" mmps.="" mmps="" mobility="" model="" more="" much="" n-terminal="" nearly="" new="" nf-="" no="" nonsteroidal="" not="" nsaids="" nuclear="" nzw="" o:p="" ocular="" of="" on="" ophthalmic="" or="" orbital="" oslg="" osmolarity="" our="" palpebral="" pbs="" peg-pla="" per="" pge2="" phosphate="" phosphosulindac="" polyethylene="" portion="" preserved="" progstaglandin="" protein="" ps-treated="" ps="" pslg="" rabbits.="" radio="" regulated="" results="" revolutions="" ripa="" rpm="" s="" safety.="" saline="" schirmer="" sd="" sds="" sem="" serum="" shift="" showed="" side="" signal="" significantly="" slg="" sodium="" standard="" stt="" studies="" suitable="" sulphate="" superior="" suppressed="" tbut="" tear="" tears="" test.="" test="" tgf-="" than="" that="" the="" time="" tosm="" transforming="" two="" ultrasonography="" units="" up="" us="" was="" were="" white="" zealand="">
No comments:
Post a Comment